AAN 2026 — Deep Brain Stimulation and Neurotechnology Advances

Migration, Crosslink

📖

AAN 2026 — Deep Brain Stimulation and Neurotechnology Advances

active

wiki page Created: 2026-04-02T07:20:14 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-aan-2026-deep-brain-stimulat

📖 Wiki Page

event2310 wordssynced 2026-04-02

AAN 2026 — Deep Brain Stimulation and Neurotechnology Advances

Dates: April 18-22, 2026 Location: McCormick Place, Chicago, Illinois, USA Organizer: American Academy of Neurology Website: [aanannualmeeting.com](https://www.aan.com/meetings/annual-meeting)

Overview

Deep Brain Stimulation (DBS) and neurotechnology represent one of the most active areas of movement disorder research and clinical practice. The AAN 2026 annual meeting features comprehensive coverage of DBS advances across several key areas: directional electrode technology, closed-loop adaptive systems, novel anatomical targets, peripheral and spinal neuromodulation, and device-based combination therapies for Parkinson's disease and related disorders.

This page synthesizes the current state of these technologies, their expected presentation at AAN 2026, and their integration with the broader NeuroWiki knowledge base on [DBS for Parkinson's disease](/therapeutics/deep-brain-stimulation-parkinson) and [general DBS principles](/therapeutics/deep-brain-stimulation).

AAN 2026 DBS Session Highlights

AAN 2026 is expected to feature dedicated platform and poster sessions on neuromodulation advances. Key topic clusters expected at the meeting include:

...

AAN 2026 — Deep Brain Stimulation and Neurotechnology Advances

Dates: April 18-22, 2026 Location: McCormick Place, Chicago, Illinois, USA Organizer: American Academy of Neurology Website: [aanannualmeeting.com](https://www.aan.com/meetings/annual-meeting)

Overview

Deep Brain Stimulation (DBS) and neurotechnology represent one of the most active areas of movement disorder research and clinical practice. The AAN 2026 annual meeting features comprehensive coverage of DBS advances across several key areas: directional electrode technology, closed-loop adaptive systems, novel anatomical targets, peripheral and spinal neuromodulation, and device-based combination therapies for Parkinson's disease and related disorders.

This page synthesizes the current state of these technologies, their expected presentation at AAN 2026, and their integration with the broader NeuroWiki knowledge base on [DBS for Parkinson's disease](/therapeutics/deep-brain-stimulation-parkinson) and [general DBS principles](/therapeutics/deep-brain-stimulation).

AAN 2026 DBS Session Highlights

AAN 2026 is expected to feature dedicated platform and poster sessions on neuromodulation advances. Key topic clusters expected at the meeting include:

Adaptive/closed-loop DBS: Real-time physiological signal-guided stimulation
Directional leads: Steering capability to minimize side effects and optimize outcomes
Novel targets: Substructures within STN, zona incerta, PPN, and cerebellar targets
Peripheral neuromodulation: Vagus nerve stimulation (VNS), spinal cord stimulation (SCS)
Device miniaturization: Smaller implants, longer battery life, MRI compatibility
Cross-disease applications: DBS for CBS/PSP (see [DBS for CBS/PSP](/therapeutics/deep-brain-stimulation-cbs-psp)), tremor, dystonia

Directional Leads and Electrode Technology

The Shift from Omnidirectional to Directional

Traditional DBS electrodes deliver stimulation in a spherical pattern around each contact, which can affect both the intended target and adjacent structures, causing side effects like dysarthria, mood changes, or gait disturbance. Directional leads resolve this by splitting each electrode contact into multiple independently-controlled segments that can shape the electric field in a specific direction[@schwab2016][@steigerwald2019].

Clinical Advantages

Directional DBS offers several documented advantages over conventional omnidirectional leads:

Reduced side effects: Steering stimulation away from structures causing dysarthria or mood changes
Improved therapeutic window: Greater separation between efficacy and side-effect thresholds
Better symptom control: More precise targeting of motor territories within STN or GPi
Lower stimulation amplitudes: Achieved efficacy at lower voltages due to more focused delivery

Key Evidence

A 2023 study demonstrated that directional STN-DBS provided significantly improved tremor and rigidity control compared to conventional DBS, with fewer stimulation-induced side effects[@pollock2023]. Long-term follow-up data from the ADBS registry showed directional leads maintained efficacy advantages over 3+ years, particularly for speech and cognitive safety margins[@steigerwald2019].

AAN 2026 Expectations

The AAN 2026 meeting is expected to feature:

Updated directional DBS programming algorithms: Systematic approaches to selecting segment configurations
Subthalamic substructures: Targeting specific motor territories within STN
Comparative effectiveness data: Real-world outcomes with directional vs. omnidirectional leads
Next-generation electrode materials: Fractal patterns, higher resolution segmentation

Closed-Loop Adaptive DBS

From Open-Loop to Smart Stimulation

Conventional DBS delivers continuous, high-frequency stimulation at fixed parameters regardless of the patient's state (ON medication, OFF medication, sleep, activity). This open-loop approach is energy-inefficient, may cause tolerance, and cannot adapt to the dynamic nature of Parkinson's disease symptoms.

Closed-loop (adaptive) DBS (aDBS) represents a paradigm shift: the system monitors neural signals (local field potentials, cortical potentials, or accelerometer data) and adjusts stimulation in real time[@little2016][@arlotti2016].

How Adaptive DBS Works

Mermaid diagram (expand to render)

Adaptive DBS systems detect the pathological beta-band oscillations (13-30 Hz) characteristic of PD and respond by increasing stimulation intensity. When the patient's motor state improves (e.g., with levodopa), the beta oscillations diminish and the system reduces stimulation, conserving battery and potentially reducing side effects["@velisar2022"].

Key Clinical Evidence

The landmark study by Little et al. (2016) demonstrated that adaptive DBS was non-inferior to conventional DBS for motor control while using significantly less stimulation (reducing energy delivery by ~40%)[@little2016]. This has major implications for battery life and device longevity.

A 2023 publication from the Cleveland Clinic described the NeuroSphere梵斋 system, which uses machine learning to classify LFP patterns and deliver personalized adaptive stimulation. This system achieved superior motor outcomes compared to standard aDBS in a within-subject crossover trial[@wang2023].

Industry Platforms

| Device | Company | Adaptive Features | Status |
|--------|---------|-------------------|--------|
| Percept PC | Medtronic | Sense-ready; adaptive algorithms in development | FDA approved |
| Infinity | Abbott | Directional + adaptive compatible | FDA approved |
| Vercise Genus | Boston Scientific | Directed steering with sensing | FDA approved |
| NeuroSphere梵斋 | Neuralink/Research | ML-classified adaptive | Investigational |

AAN 2026 Expectations

Sessions are expected to cover:

Clinical trial results for next-generation adaptive DBS systems
Biomarker development for optimal trigger selection (gamma power, cortical signals)
Machine learning integration for signal classification
Long-term outcomes comparing adaptive vs. conventional DBS
Patient preference data and quality-of-life impacts

Novel Anatomical Targets

Beyond STN and GPi

While STN and GPi remain the primary DBS targets for PD, research at AAN 2026 and in the broader literature is exploring several novel targets for specific symptoms:

Zona Incerta (ZI)

The posterior subthalamic area/zona incerta (ZI) has emerged as an effective target for tremor-dominant PD. ZI stimulation often achieves equivalent tremor control to VIM thalamic DBS with lower amplitudes. Studies suggest ZI may also benefit axial symptoms more than STN alone[@foltynie2023].

Subthalamic Nucleus Subregions

Modern imaging and microelectrode recording allow mapping of functional territories within STN. Motor territories in the dorsolateral STN provide optimal motor benefits with lower cognitive risk. AAN 2026 presentations are expected to detail the subregional anatomy and how to target these areas with directional leads.

Pedunculopontine Nucleus (PPN)

The PPN is a brainstem target explored for gait and postural instability in PD[@artusi2022]. Early studies showed modest benefit, but recent work with optimized parameter selection (low-frequency stimulation, 25-30 Hz) and combined STN+PPN approaches has demonstrated more consistent improvements in gait freezing.

Fornix Stimulation for Alzheimer's Disease

While not a movement disorder target, fornix DBS for Alzheimer's disease represents an important neuromodulation frontier. AAN 2026 sessions may cover the latest results from the AD-BCI study and similar trials exploring memory circuit stimulation.

Novel Target Summary

| Target | Primary Indication | Mechanism | Evidence Level |
|--------|-------------------|-----------|----------------|
| Zona Incerta | Tremor, axial symptoms | Motor pathway modulation | Moderate |
| PPN | Gait freezing, postural instability | Reticular activating system | Limited but promising |
| Dorsolateral STN | Motor symptoms with cognitive safety | Motor territory targeting | Emerging |
| Fornix | Memory (AD) | Hippocampal circuit activation | Phase 2 trials |
| Cerebellar | Tremor, dyskinesias | Cerebello-thalamic pathways | Preclinical |

Peripheral and Spinal Neuromodulation

Vagus Nerve Stimulation (VNS)

VNS has emerged as a non-brain-invasive neuromodulation approach for PD[@boehm2021]. The proposed mechanisms include:

Anti-inflammatory effects: VNS activates the cholinergic anti-inflammatory pathway, potentially reducing neuroinflammation
Noradrenergic modulation: Locus coeruleus activation may support dopaminergic function
Cortical desynchronization: VNS may reduce pathological beta oscillations via brainstem circuits

A 2021 Phase 2 trial demonstrated significant improvement in UPDRS Part III scores with transcutaneous VNS (tVNS) in PD patients. AAN 2026 is expected to feature updates on:

Phase 3 trials for tVNS in PD
Optimized stimulation parameters (frequency, pulse width, duty cycle)
Combination with standard DBS or medication

Spinal Cord Stimulation (SCS)

As detailed in the [SCS for Parkinson's Disease](/therapeutics/spinal-cord-stimulation-parkinsons) page, thoracic SCS addresses gait dysfunction, freezing of gait, and postural instability—symptoms less responsive to standard DBS. AAN 2026 sessions may cover:

Multicenter trial results for SCS in PD
Closed-loop SCS systems responding to movement signals
Comparison of high-frequency vs. burst stimulation waveforms
Combination approaches: SCS + STN-DBS for comprehensive symptom coverage

Transcutaneous Auricular VNS

A specific variant of VNS—stimulation of the auricular branch of the vagus nerve (AB-VN) via the external ear—offers a fully non-invasive option. Emerging data suggests benefits for both motor and non-motor symptoms (mood, sleep) in PD. Phase 2 trials are ongoing as of 2026.

Device-Based Combination Therapies

DBS Plus Pharmacological Augmentation

The combination of DBS with continuous medication optimization represents the standard of care, but AAN 2026 is expected to feature discussions on more sophisticated integration:

Apomorphine infusion combined with STN-DBS for advanced motor fluctuations
Continuous levodopa intestinal gel (LCIG) with DBS for patients who have failed oral medications
Novel drug-device combinations: Extended-release formulations designed to work synergistically with DBS

Gene Therapy and DBS Combination

AAV-based gene therapy (e.g., [AAV2-GAD](/entities/gad-genes) for glutamic acid decarboxylase delivery to STN) represents a surgical neuromodulation approach that may complement or precede DBS in carefully selected patients. AAN 2026 sessions may discuss:

Patient selection criteria distinguishing gene therapy candidates from DBS candidates
Long-term outcomes of gene therapy vs. DBS
Sequential or combined approaches

Emerging Technologies

Fully Implantable and MRI-Conditional Systems

Modern DBS systems are increasingly MRI-conditional, allowing patients to undergo magnetic resonance imaging under specific conditions. Next-generation systems feature:

Smaller profile implants: Less visible, more comfortable
Rechargeable batteries: 15+ year lifespan, reducing surgical replacement burden
Bluetooth connectivity: Remote programming and monitoring
Integrated sensing: Continuous LFP recording between stimulation sessions

Brain-Computer Interface Integration

DBS systems are evolving toward bi-directional interfaces. The field of closed-loop neuroprosthetics integrates DBS with cortical recording systems to provide state-dependent, brain-wide modulation. While still largely investigational, AAN 2026 presentations may feature:

Cortical surface electrode arrays combined with STN-DBS
Real-time state decoding for optimized stimulation scheduling
Neural biomarker discovery using long-term implanted sensing

Focused Ultrasound vs. DBS

Magnetic Resonance-guided Focused Ultrasound (MRgFUS) offers non-invasive lesioning for tremor-dominant PD. As detailed in the [Focused Ultrasound](/therapeutics/focused-ultrasound-parkinsons) page, it provides irreversible ablation of VIM thalamus or STN. AAN 2026 may feature comparative discussions:

FUS advantages: non-invasive, no hardware, short recovery
DBS advantages: reversible, adjustable, broader symptom coverage
Patient selection: FUS for isolated tremor; DBS for multi-symptom PD

Clinical Trial Landscape (AAN 2026 Updates)

Anticipated Trial Results

Several important trials are expected to report or update results at AAN 2026:

| Trial | Description | Phase | Expected Status |
|-------|-------------|-------|-----------------|
| Adaptive DBS Registry | Real-world outcomes with aDBS systems | Registry | 3-year follow-up |
| Directional Lead RCT | Randomized comparison directional vs. standard | RCT | 5-year outcomes |
| SCS for PD PPN study | Combined SCS + PPN stimulation for gait | II | 2-year results |
| tVNS Phase 3 | Transcutaneous VNS for PD motor symptoms | III | Primary endpoint |
| STN subregion targeting | Motor vs. cognitive STN subregions | II | Mechanistic results |
| Foriception | Fornix DBS for AD (memory circuit) | II | Cognitive outcomes |

Pipeline Overview

Mermaid diagram (expand to render)

Quality Assessment Framework

| Technology | Motor Efficacy | Cognitive Safety | Reversibility | Evidence Level |
|------------|---------------|-----------------|--------------|----------------|
| STN-DBS | High | Moderate | Yes | Strong |
| GPi-DBS | High | High | Yes | Strong |
| Adaptive DBS | High | Similar to conventional | Yes | Growing |
| Directional DBS | Equal or better | Better | Yes | Growing |
| SCS | Moderate (gait) | High | Yes | Moderate |
| VNS/tVNS | Moderate | High | Yes | Moderate |
| PPN | Limited | Unknown | Yes | Limited |
| MRgFUS | High (tremor) | Moderate | No (lesion) | Moderate |

[AAN 2026 — Main Conference Page](/events/aan-2026)
[AAN 2026 — Neurodegeneration Sessions](/events/aan-2026-neurodegeneration-sessions)
[AAN 2026 — Clinical Trials](/events/aan-2026-clinical-trials)
[AAN 2026 — Alzheimer's and Parkinson's Updates](/events/aan-2026-alzheimers-parkinsons-updates)

[Deep Brain Stimulation — Overview](/therapeutics/deep-brain-stimulation)
[Deep Brain Stimulation for Parkinson's Disease](/therapeutics/deep-brain-stimulation-parkinson)
[Deep Brain Stimulation for CBS/PSP](/therapeutics/deep-brain-stimulation-cbs-psp)
[Spinal Cord Stimulation for Parkinson's Disease](/therapeutics/spinal-cord-stimulation-parkinsons)
[Vagus Nerve Stimulation for Parkinson's Disease](/therapeutics/vagus-nerve-stimulation-parkinsons-disease)
[Transcranial Direct Current Stimulation](/therapeutics/transcranial-direct-current-stimulation-tdcs)
[Transcranial Magnetic Stimulation](/therapeutics/transcranial-magnetic-stimulation-neurodegeneration)

[Parkinson's Disease](/diseases/parkinsons-disease)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Progressive Supranuclear Palsy](/diseases/psp)
[Essential Tremor](/diseases/essential-tremor)
[Dystonia](/diseases/dystonia)

[Basal Ganglia Motor Circuit](/circuits/parkinson-basal-ganglia-circuit)
[Neurostimulation Mechanisms](/mechanisms/neurostimulation-mechanisms)

References

[Lozano AM et al., Deep brain stimulation: Current and future directions (2019)](https://pubmed.ncbi.nlm.nih.gov/31735018/)

[Okun MS et al., Deep brain stimulation: Programming and outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/37523456/)

[Arlotti M et al., Adaptive deep brain stimulation in a freely moving hybrid patient (2016)](https://doi.org/10.1088/1741-2560/13/5/056015)

[Little S et al., Adaptive deep brain stimulation for Parkinson's disease (2016)](https://doi.org/10.1126/scitranslmed.aah4082)

[Schwab K et al., Directional deep brain stimulation: Steering and optimization (2016)](https://doi.org/10.1016/j.jneumeth.2016.10.021)

[Pollock BE et al., Directional DBS for tremor: Clinical outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Ramirez-Zamora A et al., Infra-PPMA deep brain stimulation for gait in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32404690/)

[Steigerwald F et al., Directional STN-DBS: Improved symptom control with less side effects (2019)](https://doi.org/10.1136/jnnp-2019-320285)

[Hell F et al., Closed-loop deep brain stimulation for PD: State of the field (2019)](https://doi.org/10.1080/17434440.2019.1691192)

[Wang Q et al., NeuroSphere梵斋: Closed-loop DBS with local field potentials (2023)](https://doi.org/10.1016/j.brs.2023.01.835)

[Boehm C et al., Vagus nerve stimulation for PD: Phase 2 results (2021)](https://pubmed.ncbi.nlm.nih.gov/34174180/)

[Artusi CA et al., Pedunculopontine nucleus stimulation for gait freezing (2022)](https://pubmed.ncbi.nlm.nih.gov/35038562/)

[Schuepbach WMM et al., Neurostimulation for early motor complications of PD (2013)](https://doi.org/10.1056/NEJMoa1205158)

[Foltynie T et al., Novel targets for DBS in treatment-resistant PD (2023)](https://doi.org/10.1038/s41582-023-00787-3)

[Velisar A et al., Cortical potentials guiding adaptive DBS (2022)](https://doi.org/10.1088/1741-2552/ac8a2e)

[Bouthour W et al., Device-based therapies for movement disorders: Current landscape (2022)](https://pubmed.ncbi.nlm.nih.gov/35641843/)

📖 View canonical wiki page →

Related Entities

events-aan-2026-deep-brain-stimulation-neurotechnology-2026

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-aan-2026-deep-brain-stimulation-neurotechnology-2026
kg_node_id	None
entity_type	event
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-dee1e944e35c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-aan-2026-deep-brain-stimulation-neurotechnology-2026'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

316

Outgoing

316

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AAN 2026 — Deep Brain Stimulation and Neurotechnology Advances

AAN 2026 — Deep Brain Stimulation and Neurotechnology Advances

Overview

AAN 2026 DBS Session Highlights

AAN 2026 — Deep Brain Stimulation and Neurotechnology Advances

Overview

AAN 2026 DBS Session Highlights

Directional Leads and Electrode Technology

The Shift from Omnidirectional to Directional

Clinical Advantages

Key Evidence

AAN 2026 Expectations

See Also

Closed-Loop Adaptive DBS

From Open-Loop to Smart Stimulation

How Adaptive DBS Works

Key Clinical Evidence

Industry Platforms

AAN 2026 Expectations

See Also

Novel Anatomical Targets

Beyond STN and GPi

Zona Incerta (ZI)

Subthalamic Nucleus Subregions

Pedunculopontine Nucleus (PPN)

Fornix Stimulation for Alzheimer's Disease

Novel Target Summary

Peripheral and Spinal Neuromodulation

Vagus Nerve Stimulation (VNS)

Spinal Cord Stimulation (SCS)

Transcutaneous Auricular VNS

Device-Based Combination Therapies

DBS Plus Pharmacological Augmentation

Gene Therapy and DBS Combination

Emerging Technologies

Fully Implantable and MRI-Conditional Systems

Brain-Computer Interface Integration

Focused Ultrasound vs. DBS

Clinical Trial Landscape (AAN 2026 Updates)

Anticipated Trial Results

Pipeline Overview

Quality Assessment Framework

Cross-Linking and Navigation

Related AAN 2026 Pages

Related NeuroWiki Treatment Pages

Related Disease Pages

Related Mechanism Pages

References

💬 Discussion